MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

MDT

83.58

-0.61%↓

VEEV

225.8

+0.45%↑

A

105.71

+0.08%↑

WBA

10.98

-0.18%↓

CHE

548.09

-0.97%↓

Search

Lexicon Pharmaceuticals Inc

Abierto

SectorSanidad

0.75 1.35

Resumen

Variación precio

24h

Actual

Mínimo

0.7

Máximo

0.79

Métricas clave

By Trading Economics

Ingresos

31M

-34M

Ventas

25M

27M

BPA

-0.09

Margen de beneficios

-127.16

Empleados

103

EBITDA

30M

-30M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 Meses

+646.27% upside

Dividendos

By Dow Jones

Próximas Ganancias

1 may 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

102M

208M

Apertura anterior

-0.6

Cierre anterior

0.75

Puntuación técnica

By Trading Central

Confianza

Strong Bullish Evidence

Lexicon Pharmaceuticals Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

1 nov 2024, 12:42 UTC

Principales Movimientos del Mercado

Lexicon Pharma Shares Slide Premarket After Negative FDA Panel Vote

Comparación entre iguales

Cambio de precio

Lexicon Pharmaceuticals Inc previsión

Precio Objetivo

By TipRanks

646.27% repunte

Estimación a 12 Meses

Media 5 USD  646.27%

Máximo 6 USD

Mínimo 4 USD

De acuerdo con 3 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Lexicon Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

3 ratings

2

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

0.501 / N/ASoporte y Resistencia

Corto Plazo

Strong Bullish Evidence

Medio plazo

Strong Bullish Evidence

Largo Plazo

Bearish Evidence

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Lexicon Pharmaceuticals Inc

Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract. Lexicon Pharmaceuticals, Inc. has strategic collaboration and license agreements with Bristol-Myers Squibb Company and Genentech, Inc. The company was incorporated in 1995 and is headquartered in The Woodlands, Texas.